Evidence map›Paper›PMID 39586373›Full record

ArticleJournal of advanced research2025

Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset gastric cancer: A retrospective cohort study.

Yingxue Liu, Xiaoyan Zhang, Lu Gan, Zhikai Chen, Xin Wang, Jiayu Zhang, Jie Chen, Cong Tan, Weiqi Sheng, Midie Xu

Abstract read
In one paragraph

Article in Journal of advanced research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Pronounced ethnic and sex disparities in gastric cancer burden and healthcare utilization in Inner Mongolia: a 9-year population-based cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yingxue LiuDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Institute of Pathology, Fudan University, Shanghai 200032, China.
Xiaoyan ZhangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Institute of Pathology, Fudan University, Shanghai 200032, China.
Lu GanDepartment of Medical Oncology, Fudan University Zhongshan Hospital, Shanghai 200032, China.
Zhikai ChenShanghai Medical College, Fudan University, Shanghai 200032, China.
Xin WangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Institute of Pathology, Fudan University, Shanghai 200032, China.
Jiayu ZhangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Institute of Pathology, Fudan University, Shanghai 200032, China.
Jie ChenDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Second Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Cong TanDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Institute of Pathology, Fudan University, Shanghai 200032, China.
Weiqi ShengDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Institute of Pathology, Fudan University, Shanghai 200032, China. Electronic address: shengweiqi2006@163.com.
Midie XuDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Institute of Pathology, Fudan University, Shanghai 200032, China. Electronic address: xumd27202003@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study investigates the differences between early-onset gastric carcinoma (EOGC) and late-onset gastric carcinoma (LOGC) by examining trends, demographics, clinical and molecular features, treatments, and outcomes at a leading cancer center in China.

objectivesTo delineate the distinctions between EOGC and LOGC in terms of patient characteristics, disease progression, and treatment outcomes, and to suggest appropriate screening strategies.

methodsWe analyzed 18,877 gastric carcinoma cases treated at Fudan University Shanghai Cancer Center (FUSCC) from 2000 to 2022. Descriptive statistics were performed using IBM SPSS. Survival rates were assessed via the Kaplan-Meier method and log-rank test, while COX regression analysis identified factors affecting disease-free survival (DFS) and overall survival (OS).

resultsThe average age of gastric cancer diagnosis has increased slightly since 2000, with a steady rise in both EOGC and LOGC cases, though EOGC's proportion has slightly decreased. EOGC had a higher proportion of female patients and was more common in the gastric body and antrum pylorus. EOGC cases showed lower levels of cancer biomarkers, HER2 expression, vascular and lymphatic invasion, and lower differentiation and invasion depth. They also exhibited more advanced N and TNM staging, Borrmann IV type, and low adhesive carcinoma. EOGC underwent more extensive D2 lymphadenectomy and neoadjuvant chemotherapy. There were no significant differences in Claudin18.2 and MMR protein status between EOGC and LOGC. EOGC had higher rates of ovarian and peritoneal metastases, with a better early prognosis but faster late-stage progression.

conclusionEOGC and LOGC cases have increased over the past two decades. EOGC presents unique clinical and pathological features, requiring thorough surgical treatment and has a better early prognosis but more rapid late-stage progression. Enhanced screening for younger adults is recommended to address the rising EOGC trend.

Indexed as

Stomach NeoplasmsAdultAgedAge of OnsetBiomarkers, TumorChinaFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesBiomarkers, TumorCharacteristics and prognosisDisease-free survivalEarly-onset gastric cancerLate-onset gastric cancerOverall survival

Identifiers

PMID39586373
PMCPMC12789716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.